Cerus Corporation

CERS Healthcare Medical Devices

Revenue
+6.28%
EPS
−2,800.0%
Free cash flow
+2,471.3%
Total debt
−25.4%

Quarter to September 2026, against a year earlier

2.03 0.10 −4.69%
Market cap
$430.2M
P/E
0.0×
Fwd P/E
−65.1×
Dividend yield
—
F-score
5/9
Altman Z
−4.00
Beneish M
−2.87
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
1.91 2.36 1.44 1.68
P/FCF ratio
971.53 0.00 0.00 354.35
P/Operating CF
159.61 (220.09) (115.89) 63.33
P/B ratio
6.29 8.28 5.17 6.04
EV/Sales
1.93 2.40 1.46 1.68
EV/EBITDA
0.00 9,004.57 0.00 0.00
EV/FCF
984.16 (324.93) (293.71) 355.26
Current Ratio
1.96 1.83 1.63 1.73
Net Debt/EBITDA
7.76 (6.19) 47.38 (4.07)
Debt/Equity
0.83 0.92 1.24 1.29
Earnings Yield
(1.59%) (1.20%) (2.75%) (3.89%)
Free Cash Flow Yield
0.10% (0.31%) (0.34%) 0.28%
Free Cash Flow per Share
0.01 (0.02) (0.02) 0.03
Book value per Share
0.38 0.35 0.35 0.34
Free Cash Flow
2.42 (3.53) (3.28) 4.89
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026